logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Overactive Bladder

    FiltersReset Filters
    7 results

    • botox

      (onabotulinumtoxinA)
      Allergan, Inc.
      Usage: BOTOX is indicated for treating adult overactive bladder, detrusor overactivity due to neurologic conditions, chronic migraine prophylaxis, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, and blepharospasm or strabismus in patients 12 years and older. It's also approved for neurogenic detrusor overactivity in children aged 5 and older.

    • detrol la

      (tolterodine tartrate)
      Viatris Specialty LLC
      Usage: DETROL LA Capsules are indicated for treating overactive bladder symptoms, including urge urinary incontinence, urgency, and frequency.

    • gemtesa

      (vibegron)
      Sumitomo Pharma America, Inc.
      Usage: GEMTESA® is indicated for the treatment of overactive bladder (OAB) in adults, characterized by urge urinary incontinence, urgency, and urinary frequency. It is also indicated for adult males with OAB symptoms who are undergoing pharmacological therapy for benign prostatic hyperplasia (BPH).

    • myrbetriq

      (mirabegron)
      Astellas Pharma US, Inc.
      Usage: MYRBETRIQ is indicated for treating adult overactive bladder (OAB) symptoms, including urge urinary incontinence, urgency, and urinary frequency, either alone or with solifenacin succinate. It is also indicated for pediatric patients (ages 3+) with neurogenic detrusor overactivity (NDO) who weigh 35 kg or more.

    • oxybutynin chloride

      (Oxybutynin Chloride)
      Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
      Usage: Oxybutynin chloride tablets are indicated for relieving bladder instability symptoms in patients with uninhibited neurogenic or reflex neurogenic bladder, including urgency, frequency, urinary leakage, urge incontinence, and dysuria.

    • solifenacin succinate

      (solifenacin succinate)
      Ajanta Pharma USA Inc.
      Usage: Solifenacin succinate is used to treat adults with overactive bladder symptoms, including urge urinary incontinence, urgency, and urinary frequency.

    • toviaz

      (fesoterodine fumarate)
      U.S. Pharmaceuticals
      Usage: Toviaz is indicated for treating overactive bladder (OAB) in adults, alleviating symptoms such as urge incontinence, urgency, and frequency. It is also used for pediatric patients aged 6 years and older with neurogenic detrusor overactivity (NDO) who weigh over 25 kg.